AstraZeneca ASCO 2021 data support ambition to revolutionise cancer outcomes by treating earlier and transforming the patient experience pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
AstraZeneca : ASCO 2021 Data Support Ambition to Revolutionize Cancer Outcomes by Treating Earlier and Transforming the Patient Experience
05/19/2021 | 05:06pm EDT
Send by mail :
Message :
Required fields
LYNPARZA is the first targeted medicine to show clinical benefit in the adjuvant setting for patients with germline BRCA-mutated high-risk HER2-negative early breast cancer
CALQUENCE shows sustained four-year clinical benefit in 1st-line chronic lymphocytic leukemia and lower atrial fibrillation rates in previously treated patients vs. ibrutinib
IMFINZI five-year data represent longest-ever survival reported in a Phase III immunotherapy trial in unresectable Stage III lung cancer
AstraZeneca will present new data underscoring its ambition to redefine cancer care at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 4 to 8, 2021.
Imfinzi, tremelimumab combo boosts survival in lung cancer
7th May 2021
A combination of AstraZeneca s Imfinzi (durvalumab), tremelimumab and chemotherapy has extended overall survival (OS) when used as a first-line treatment for metastatic non-small cell lung cancer (NSCLC).
A final analysis of data from the POSEIDON study shows that the combination demonstrated a statistically significant and clinically meaningful OS benefit versus chemotherapy alone.
The trial also tested a combination of Imfinzi plus chemotherapy which, while showing a statistically significant improvement in progression-free survival (PFS) versus chemotherapy, failed to significantly improve OS.
Each combination demonstrated an acceptable safety profile, and no new safety signals were identified, AZ noted.
Top UK Stocks to Watch: IHG expects recovery to gain momentum
Joshua Warner May 7, 2021 9:01 AM
IHG hopes to be on the road to recovery, IAG calls for governments to do more to let international travel resume, St Modwen shares jump following a takeover offer, AstraZeneca sees positive results from its lung cancer trial, and three companies prepare to IPO in London. Share:
Top News: IHG sees pick-up in demand in Americas and China
InterContinental Hotels Group said it saw a significant improvement in demand in March and April, led by improvements in the Americas and China, and said it expects momentum to build this year as the world comes out of the pandemic and ease restrictions.
Imfinzi and tremelimumab with chemotherapy demonstrated overall survival benefit in POSEIDON trial for 1st-line Stage IV non-small cell lung cancer but a trend in overall survival did not achieve statistical significance POSEIDON was a Phase III trial of AstraZeneca s Imfinzi (durvalumab) plus platinum-based chemotherapy or Imfinzi, tremelimumab and chemotherapy versus chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC). Positive high-level results from the final analysis of POSEIDON showed the combination of Imfinzi, tremelimumab and chemotherapy demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone. This immunotherapy combination also demonstrated a statistically significant improvement in progression-free survival (PFS) versus chemotherapy alone